Navigation Links
AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
Date:11/5/2013

REDWOOD CITY, Calif., Nov. 5, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX),  a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2013.

"With the submission of our NDA at the end of September for Zalviso™, AcelRx has commenced activities related to an anticipated U.S. commercial launch," stated Richard King, president and CEO of AcelRx.  "We also continue to actively participate in key medical meetings worldwide to increase awareness of the results from our completed Zalviso Phase 3 clinical trials among a broad audience of medical professionals involved in pain treatment.  Having appointed our Chief Commercial Officer last quarter, we are working diligently to prepare Zalviso to be well positioned for launch in the US market, subject to regulatory approval."

Third Quarter and Nine Months Financial ResultsNet loss for the third quarter of 2013 was $11.0 million, or $0.26 per share, compared with a net loss of $8.6 million, or $0.38 per share for the third quarter of 2012.  The adjusted net loss for the third quarter of 2013 was $8.6 million, or $0.21 per share and excludes a $2.4 million non-cash expense resulting from the liability accounting related to warrants issued in connection with the PIPE financing completed in June 2012.  There was no such expense recorded in the third quarter of 2012.

During the third quarters of 2013 and 2012, AcelRx recognized revenue of $0.5 million and $0.2 million, respectively, as reimbursement for work completed under a research grant from the U.S. Army Medical Research and Materiel Command, or USAMRMC, for development of ARX-04, a sufentanil NanoTab product candidate for the treatment of moderate-to-severe acute pain
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
2. David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
3. AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
4. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
5. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
6. AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
7. AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares
8. AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013
9. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
10. AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
11. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... keynote address last month that industry is compelled to ... to gain the efficiencies—and develop the transformational innovations -- ... Barsoum,s comments were preceded by Doug Kohrs , ... OMTEC moderator, who stressed that industry must add "episode ...
(Date:7/30/2015)... YORK , July 30, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Biosensors Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... WOONSOCKET, R.I., Dec. 11 CVS Caremark (NYSE: ... Senior Vice President and Chief Human Resources Officer, effective January ... announced his retirement. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) ... Caremark, has more than 30 years of human resources experience. ...
... , OXFORD, England, December 11 ... Ii Clinical Results With cat,Allergy T-cell Vaccine , ... Into,Late-Stage Development , Circassia Ltd, a ... completed a GBP15 million ($25 million),fundraising. The investment round, which ...
Cached Medicine Technology:CVS Caremark Names New Chief Human Resources Officer 2Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... The ... Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders ... the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports ... , Instead of risking containment — or even destruction — of products, an ...
(Date:7/31/2015)... Vancouver, BC (PRWEB) , ... July 31, 2015 ... ... Rehab, has recently published a blog post that encourages the understanding and treatment ... and many people opt for in-home remedies. This can be dangerous if the ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... announce that their latest designer handbag line will be named for Madeline Stuart, ... sensation as the first globally recognized model with Down syndrome, gracing the front ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... selected as a contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication ... to help long-term and post-acute care providers understand the benefits of using ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... Healthy Directions, LLC, is proud to announce the launch of searchjointpain.com, a ... conditions and solutions. , ... Potomac, MD (PRWEB) February 27, 2009 -- ... to announce the launch of searchjointpain.com , a new informational Web ...
... LLC announces the implementation of its rehabilitation software by ... for Southeast Missouri Hospital, a 269-bed regional medical complex ... includes functionality for electronically managing therapy documentation, scheduling, referrals, ... ...
... of the most expensive benefit claims made by members. , ... Melbourne, ... complex bowel surgery heads the annual Medibank Private "Chart Toppers" list of ... of the fund., , ,The bowel surgery claim, costing 20 per cent ...
... Directors Recommends Shareholders Accept the A$318 Million Offer, ... Company Offers Strong Technology Platform and Phase II ... 27 Cephalon, Inc . (Nasdaq: ... subsidiary, Cephalon International Holdings, Inc., intends to make ...
... Asian AffiliateNEW YORK and SINGAPORE, Feb. 26 ... services, has signed an affiliation agreement with Parkway ... based in Singapore and a subsidiary of Parkway ... programs throughout Asia. Under the agreement, ParkwayHealth will ...
... affects approximately 250,000 people in the United States, occurs ... or fatty tissue and loses function. While scientists have ... curing the disease, another part of the mystery has ... University of Missouri scientist and his team have identified ...
Cached Medicine News:Health News:Healthy Living Network Announces Launch of New Joint Pain Web Site 2Health News:Southeast Missouri Hospital Implements Chart Links Rehabilitation Software for Therapists 2Health News:Southeast Missouri Hospital Implements Chart Links Rehabilitation Software for Therapists 3Health News:Health Insurance Claims Top $2 Million Mark 2Health News:Health Insurance Claims Top $2 Million Mark 3Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 2Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 3Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 4Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 5Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 6Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 7Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 8Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 9Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 10Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 11Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 12Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 3Health News:Muscular dystrophy mystery solved; Mizzou scientist moves closer to MD solution 2
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... synthesized in the parafollicular C-cells of the ... granules. The major action of calcitonin is ... osteoclast activity, resulting in decreased mobilization of ... most evident in conditions associated with high ...
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
Erbium Laser with Sapphire Erbium Handpiece for Dermatological and Cosmetic Surgery...
Medicine Products: